Abstract : Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-ω (IFN-ω) (13 patients), against the 13 types of IFN-α (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men.
https://hal-pasteur.archives-ouvertes.fr/pasteur-03263254 Contributor : Laurence LanglaisConnect in order to contact the contributor Submitted on : Thursday, June 17, 2021 - 10:28:35 AM Last modification on : Monday, May 9, 2022 - 11:58:08 AM Long-term archiving on: : Saturday, September 18, 2021 - 6:13:30 PM
Paul Bastard, Lindsey Rosen, Qian Zhang, Eleftherios Michailidis, Hans-Heinrich Hoffmann, et al.. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, American Association for the Advancement of Science (AAAS), 2020, 370 (6515), pp.eabd4585. ⟨10.1126/science.abd4585⟩. ⟨pasteur-03263254⟩